How Many Radiation Treatments for Prostate Cancer: What It Means, What to Expect and When to See a Specialist

The first thing many men do after a radiation consultation is not read the leaflet. They open a calendar. Thirty-nine weekday appointments, or twenty, or five, suddenly have to fit around a job, a grandchild’s school run and a spouse who also needs the car. The question “how many treatments?” is really a question about how life will look for the next two months.

The honest answer is that there is no single number. Prostate cancer radiation has changed more in the past decade than in the thirty years before it, and the same cancer can now be treated on schedules that differ by a factor of eight. Understanding why a doctor recommends one course over another turns a bewildering timetable into a reasoned plan.

This guide walks through the real numbers from published trials and major health services, explains what shapes them, and sets out what a course feels like from the first planning scan to the follow-up blood tests years later.

Why "how many radiation treatments" has several correct answers

Radiation oncologists talk about fractions, not treatments. A fraction is one session, and the total course is a set amount of radiation divided into a chosen number of sessions. Split the same total into fewer, larger fractions and the course shortens. Split it into more, smaller fractions and it lengthens. The biology of prostate cancer cells is what makes this flexible.

Prostate tumors are, in radiobiology terms, slow-growing and unusually sensitive to larger individual fractions. Healthy bladder and rectal tissue nearby respond differently. For decades the safe assumption was that many small sessions protected those organs best, which is why courses of seven to eight weeks became standard. Better imaging, tighter beam shaping and daily position checks changed the trade-off, and large randomized trials then tested shorter schedules head to head.

The result is a menu rather than a rule. According to the NHS, external radiotherapy for prostate cancer is usually given as a series of short daily sessions on weekdays over several weeks, and internal radiotherapy can be delivered in one or a few procedures. The three broad families are conventional fractionation, moderate hypofractionation and ultra-hypofractionation (often called stereotactic body radiotherapy), plus brachytherapy. Each carries a different number of visits, and each is examined in turn below.

How many sessions does conventional external beam radiation take?

The classic course is the one most men picture: a visit every weekday, Monday through Friday, for seven to eight weeks. Major clinical references describe external beam radiation for prostate cancer as typically delivered five days a week over several weeks, with weekends off to let normal tissue recover. In the largest UK trial of fractionation, the conventional arm used 37 sessions, and older schedules of 39 sessions remain in use in some centers.

Each appointment is brief. The treatment itself lasts a few minutes; changing, positioning and image checks account for most of a 15 to 30 minute slot. Men frequently drive themselves, and many continue working throughout.

Why would anyone still choose the long course when shorter ones exist? A few reasons remain sensible. Men with large prostates, significant pre-existing urinary symptoms or inflammatory bowel conditions may tolerate smaller daily fractions better. Some situations, such as treating the pelvic lymph nodes or giving radiation after surgery to the prostate bed, still commonly use conventional or near-conventional schedules because the evidence for shortening them is less mature. And some men simply prefer the familiar, gradual approach once side effects have been explained.

The conventional course is not outdated. It is the reference standard against which every shorter schedule has been measured, and the trials that follow only make sense in comparison with it.

Moderate hypofractionation: the 20-session course explained

The most influential change in prostate radiation came from a trial with an awkward acronym, CHHiP, published in The Lancet Oncology in 2016. It randomized more than 3,200 men with localized prostate cancer to either the conventional 37-session course over about seven and a half weeks or a 20-session course delivered over four weeks. The question was simple: could the short course match the long one without more harm?

It could. At five years, the proportion of men free of biochemical or clinical failure was roughly 91% with the 20-session schedule and about 88% with the conventional schedule, meeting the trial’s definition of non-inferiority. Bowel and bladder side effects at two years were similar between the arms. On the strength of these findings, 20 sessions over four weeks became the standard external beam schedule across the UK and much of the world for men with low- and intermediate-risk disease, and it is widely used for higher-risk disease too.

Consider what this means in practical terms. A man who would have spent 37 weekday mornings at a treatment center now spends 20. The course wraps in a month rather than nearly two. For anyone traveling a long distance, that is 17 fewer round trips.

Trial results do not automatically apply to every individual, and clinicians still adapt the schedule to prostate size, urinary function and whether nodes are being treated. But when a specialist offers “four weeks of radiotherapy,” this is the evidence behind the offer.

Stereotactic radiotherapy: can prostate cancer really be treated in five sessions?

Yes, for suitably selected men, and this is the schedule generating the most conversation in waiting rooms. Stereotactic body radiotherapy, sometimes abbreviated SBRT and described by clinical references as delivering treatment in five or fewer sessions, uses very precise imaging and beam shaping to give large fractions to the prostate while sparing the rectum and bladder. Courses are commonly spread over one to two weeks, often on alternate days.

The precision is the point. Because each session delivers a much larger share of the total course, the margin for error shrinks. Centers offering SBRT typically use daily imaging, implanted markers or a rectal spacer to hold position, and rigorous bladder and bowel preparation. Sessions run longer than conventional ones, often 20 to 40 minutes on the table, because so much of the time is spent verifying alignment.

Where does the evidence stand? Large randomized trials comparing five-session SBRT with 20- or 39-session courses in low- and intermediate-risk disease have reported similar cancer control in the medium term and broadly comparable side-effect profiles, with some differences in the pattern and timing of urinary symptoms. Longer follow-up is still accumulating, which is why many guideline bodies describe SBRT as an appropriate option for low- and favorable intermediate-risk disease rather than a universal replacement.

What the evidence does not yet show is how SBRT performs in high-risk disease or in men with large glands and troublesome urinary symptoms. For those groups, the 20-session course remains the better-supported choice.

Brachytherapy: how many treatments is internal radiation?

Brachytherapy turns the question inside out. Instead of aiming beams from outside, a specialist places radioactive sources directly in the prostate under anesthesia, guided by ultrasound. Clinical references describe two forms, and the number of visits differs sharply between them.

Low-dose-rate brachytherapy involves permanent implantation of tiny sealed seeds, typically in a single procedure lasting an hour or two with a same-day or overnight stay. The seeds release radiation gradually over weeks to months and then become inert; they are never removed. For a man with low- or favorable intermediate-risk cancer and a moderate-sized prostate, the entire course of radiation can therefore be one appointment plus follow-ups.

High-dose-rate brachytherapy uses a temporary source threaded through thin tubes placed in the prostate, delivering treatment over minutes before everything is withdrawn. It may be given as one session or a small number of sessions, sometimes combined with a shortened external beam course for higher-risk disease.

Brachytherapy is not for everyone. Men with very large prostates, significant urinary obstruction or a previous transurethral prostate operation may be poor candidates because the implant can worsen urinary symptoms. The procedure requires anesthesia, and urinary irritation in the first months is often more pronounced than with external beam treatment. Still, for the right man, trading weeks of daily visits for a single procedure is a genuine and evidence-supported option worth raising with the treating team.

Radiation schedules side by side: sessions, weeks and who they suit

Numbers scattered across paragraphs are hard to hold in mind. The table below gathers the typical schedules as described by the NHS, major clinical references and the CHHiP trial. Every center adjusts these to the individual, so treat it as orientation rather than a promise.

Approach	Typical number of sessions	Usual span	Commonly considered for
Conventional external beam	37 to 39	7 to 8 weeks, weekdays	Large glands, marked urinary symptoms, nodal or post-surgery treatment
Moderate hypofractionation	20	4 weeks, weekdays	Most localized disease; current standard in many countries
Stereotactic (SBRT)	5 or fewer	1 to 2 weeks, often alternate days	Low and favorable intermediate risk at experienced centers
Low-dose-rate brachytherapy	1 procedure	Single day, seeds remain	Low and favorable intermediate risk, moderate gland size
High-dose-rate brachytherapy	1 to a few	Days to 2 weeks, sometimes with external beam	Intermediate and high risk as a boost or alone

Two patterns stand out. First, fewer sessions does not mean less treatment; the total radiation is comparable, simply divided differently. Second, the shortest schedules are concentrated in lower-risk disease, where the evidence is longest and the target is most predictable. As follow-up from ongoing trials lengthens, those boundaries may move, but they reflect what the evidence supports today.

What decides how many radiation treatments you personally will have?

The number on a man’s treatment calendar emerges from a handful of factors weighed together at a multidisciplinary meeting. Understanding them makes the recommendation feel less arbitrary.

Risk group comes first. Clinicians combine the PSA level, the Gleason grade from the biopsy and the clinical stage into low, intermediate or high risk. Lower-risk disease opens the door to the shortest schedules and to brachytherapy alone. High-risk disease more often means a 20-session or longer course, possibly including the pelvic lymph nodes, combined with hormone therapy.

Prostate size and urinary function matter almost as much. A very large gland or a man who already wakes several times a night to urinate may fare worse with large fractions or seed implants. Previous pelvic surgery, inflammatory bowel disease, hip replacements that complicate imaging and certain connective tissue conditions also nudge decisions toward conventional fractionation.

Then there is the practical layer: distance to the treatment center, work commitments, whether a man can lie still for 30 minutes and whether a center has the imaging and experience for stereotactic work. None of these is trivial, and good teams ask about them.

Finally, patient preference is legitimate. Where the evidence shows two schedules perform similarly, choosing the one that fits a life better is not a compromise on quality; it is what shared decision-making is for.

What to expect at each radiation session, from planning scan to final day

Before any treatment, there is a planning visit that men often find the most involved appointment of the whole course. A CT scan, sometimes with an MRI, maps the prostate and surrounding organs. Small skin marks or tattoos the size of a freckle guide daily positioning. Some centers place tiny gold markers in the prostate a week or two beforehand, or inject a temporary gel spacer between prostate and rectum, each under local anesthesia.

Bladder and bowel preparation becomes a daily ritual. Most protocols ask for a comfortably full bladder and an empty rectum at every session, because a full bladder lifts the small bowel out of the beam and a consistent rectum keeps the prostate from shifting. Men learn to time a set amount of water before each appointment with surprising precision.

On treatment days, the sequence rarely varies: change, lie on the couch in the planning position, a brief imaging check, then the machine rotates around the body for a few minutes. Nothing is felt. There is no heat, no sensation, no radioactivity carried home. Total time in the department is usually under half an hour for conventional courses and somewhat longer for stereotactic ones.

A radiographer or therapist sees the patient daily, and a doctor or nurse reviews symptoms weekly. That regular contact is one of the underappreciated features of a radiation course: problems are caught early because someone is looking every day.

Radiation side effects: what is common, what is temporary and what can last

Side effects follow a timeline more than a checklist. According to the NHS and other major references, the early effects of prostate radiotherapy build over the second half of the course and peak around its end or the week or two after, then settle over several weeks to a few months.

Urinary symptoms lead the list: passing urine more often, urgency, a weaker stream, burning and getting up at night. Bowel changes come next, including looser or more frequent stools, urgency and occasionally rectal soreness or a little bleeding. Tiredness accumulates, especially in men also on hormone therapy or traveling long distances. Skin reactions are usually mild because the beams pass through the pelvis rather than concentrating on skin.

Later effects are less common but matter more to long-term quality of life. Erectile difficulties may develop gradually over one to two years as small blood vessels are affected. A minority of men experience persistent bowel changes or rectal bleeding, and a smaller number have long-term urinary irritation or, rarely, narrowing of the urethra. Infertility should be assumed.

Shorter courses do not simply mean fewer side effects. The CHHiP trial found comparable bowel and bladder effects between 20 and 37 sessions at two years, and stereotactic trials report broadly similar totals with some differences in timing. What the shorter courses reliably reduce is disruption, not necessarily symptoms. Managing those symptoms is a job for the treating team, who have effective approaches for most of them.

Is it better to treat prostate cancer with surgery or radiation?

This question has a rare thing in medicine: a long randomized trial that actually answers it. The UK ProtecT study assigned more than 1,600 men with PSA-detected localized prostate cancer to active monitoring, surgical removal of the prostate or radiotherapy with short-course hormone therapy, then followed them for a median of 15 years. The results were published in the New England Journal of Medicine in 2023.

Death from prostate cancer was uncommon in every group, about 3% overall, and did not differ significantly between surgery, radiotherapy and monitoring. Metastatic disease was more frequent in the monitoring arm, at roughly 9%, than in the surgery and radiotherapy arms, at about 5% each. Between surgery and radiotherapy, cancer outcomes were essentially equivalent.

What differed was the shape of the side effects. Surgery caused more urinary incontinence and earlier, more pronounced erectile dysfunction. Radiotherapy caused more bowel symptoms and a slower decline in sexual function, partly related to the hormone therapy. Over a decade, some differences narrowed, but the pattern held.

So the fair answer is that neither is better for the cancer in localized disease; they are different for the man. A 58-year-old marathon runner who dreads incontinence and a 74-year-old with bowel disease who dreads more bowel trouble may reasonably reach opposite decisions from the same evidence. Both are right.

Can prostate cancer be 100% cured, and what is life expectancy after radiation?

Doctors avoid the word “cure” for a careful reason, and it is not evasion. Prostate cancer can recur many years after apparently successful treatment, so certainty at any single moment is impossible. What the evidence does support is that for localized disease, the great majority of men treated with radiation will not die of prostate cancer.

ProtecT offers the clearest long-horizon numbers: at 15 years, roughly 97% of men in every arm had not died from prostate cancer, including the radiotherapy arm. Population statistics from national cancer registries point the same way, with five-year relative survival for localized and regional disease approaching that of men without the diagnosis. These are group figures, not personal forecasts, and men with high-risk or node-positive disease face higher recurrence rates than those numbers imply.

Life expectancy after prostate radiation, for most men, is therefore governed less by the cancer than by everything else: heart health, diabetes, smoking, activity. That is a striking and underappreciated point. A man who leaves his final radiation session and then neglects his blood pressure has likely misjudged where his risk lies.

What no one can promise is an individual outcome. Biology varies, and a small proportion of cancers behave aggressively despite favorable-looking features. The honest framing is that radiation offers a very good chance of long-term control, that monitoring continues for years precisely because certainty is unattainable, and that most men live long lives after treatment.

Can prostate cancer come back after radiation treatment?

It can, and follow-up is designed around that possibility. After radiation, the prostate remains in the body, so the PSA blood test does not drop to zero as it does after surgery. Instead it falls gradually over one to two years to a low point, called the nadir. Clinical references describe this slow decline as expected, and a low, stable PSA is the reassuring pattern doctors look for.

Two things can confuse men reading their own results. The first is the PSA bounce, a temporary rise, usually within the first three years, that then settles without any cancer being present. It is more common after brachytherapy and in younger men and is not a recurrence. The second is the definition of recurrence itself: a rise of a set amount above the nadir on repeated tests, not a single value. A single higher reading prompts a repeat, not a panic.

Recurrence rates depend heavily on the starting risk group. In the CHHiP trial, around nine in ten men with predominantly low- and intermediate-risk disease remained free of biochemical or clinical failure at five years. Men with high-risk disease have higher rates, which is why hormone therapy and, at times, treatment of the pelvic nodes are added for them.

If recurrence is confirmed, options exist, including imaging to locate the disease, further local treatment in selected cases and systemic therapy. Those decisions belong with the specialist team, but the point for a man finishing radiation is that follow-up is a safety net, not a countdown.

Why hormone therapy is often paired with radiation, and for how long

Many men are surprised to learn that a course of radiation comes with a second treatment attached. Prostate cancer cells depend on testosterone to grow, and hormone therapy works by lowering testosterone or blocking its action on those cells. When given alongside radiation, it appears to make cancer cells more vulnerable to the radiation, shrinks the prostate so the target is smaller, and treats microscopic disease outside the beam.

The NHS describes hormone therapy being used before, during and after radiotherapy for intermediate- and high-risk disease. The duration is where individual planning matters most. For intermediate-risk cancer, courses of several months are typical. For high-risk disease, treatment commonly continues for a period of years, because trials have shown longer courses improve control in that group. Low-risk cancer treated with radiation usually needs no hormone therapy at all.

The mechanism explains the side effects. Reduced testosterone brings hot flushes, tiredness, loss of libido, some muscle loss and, over longer courses, effects on bone density and metabolic health. These reverse for most men after treatment stops, though testosterone recovery can take many months and is slower in older men.

Exact agents, how they are given and how long to continue are decisions for the prescribing clinician, weighed against a man’s cardiovascular health and priorities. What every man deserves is to know in advance that the radiation calendar may be short while the hormonal effects last longer, so neither comes as a surprise.

When to see a specialist: red flags during and after prostate radiation

Most side effects of prostate radiation are expected and manageable by the treating team at routine reviews. A few situations should not wait for the next scheduled appointment. Seek urgent care if you cannot pass urine at all, notice heavy rectal or urinary bleeding rather than light staining, develop a fever with shivering or burning on urination, have severe abdominal or pelvic pain, or experience sudden calf swelling or breathlessness, which can signal a blood clot. During treatment, the radiation department wants to hear about these the same day.

After treatment ends, follow-up typically involves PSA tests every few months at first, spacing out over the years. See a specialist between visits if a PSA result rises on two consecutive tests, if new bone pain develops without an obvious cause, if urinary symptoms worsen sharply after having settled, or if bowel bleeding persists beyond the first few months.

There is also a quieter category of reasons to speak up. Erectile changes, mood effects from hormone therapy, hot flushes that disrupt sleep and persistent fatigue are all legitimate topics for a clinic visit, and effective support exists for each. Men frequently under-report them, assuming they are the price of treatment. They are not a price to be paid in silence.

A good rule: if a symptom is new, severe or getting worse, call. The team would far rather hear about something minor than learn about something serious late.

Frequently asked questions

How many radiation treatments are typical for prostate cancer?

Most men receive 20 sessions over four weeks or, less commonly now, 37 to 39 sessions over seven to eight weeks, given on weekdays. Stereotactic courses use five or fewer sessions across one to two weeks, and brachytherapy may need a single procedure. The number depends on risk group, prostate size, urinary symptoms and whether hormone therapy or lymph node treatment is planned, so schedules are tailored to the individual.

Can prostate cancer be 100% cured with radiation?

No treatment can promise a 100% cure, because prostate cancer can recur years later and certainty at any moment is impossible. What long trials show is that the large majority of men treated for localized disease never die of prostate cancer; in ProtecT, about 97% were alive without prostate cancer death at 15 years. Higher-risk disease carries greater recurrence rates, which is why follow-up continues for years after treatment.

Is it better to treat prostate cancer with surgery or radiation?

For localized disease, the ProtecT trial found no significant difference in prostate cancer death between surgery and radiotherapy at 15 years, and metastasis rates were similar at about 5% in each. The two differ in side effects: surgery causes more urinary leakage and earlier erectile problems, while radiation causes more bowel symptoms and slower sexual decline. The better choice depends on a man’s health, anatomy and what he most wants to avoid.

What is the life expectancy after prostate radiation?

For most men with localized prostate cancer, life expectancy after radiation is shaped more by heart health, diabetes and other conditions than by the cancer itself. Long-term trial data show prostate cancer death around 3% at 15 years after radiotherapy for PSA-detected disease. Men with high-risk or node-positive cancer face higher recurrence risk, and individual outcomes vary, so these are group figures rather than personal predictions.

Can prostate cancer come back after radiation treatment?

Yes, recurrence is possible, which is why PSA is monitored for years afterward. Recurrence is defined by a sustained rise above the lowest post-treatment PSA on repeated tests, not a single reading. In the CHHiP trial, roughly nine in ten men with mostly low- and intermediate-risk disease remained free of failure at five years. If recurrence is confirmed, imaging and further treatment options are discussed with the specialist team.

Why is a five-session course not always offered?

Stereotactic radiotherapy requires precise imaging, positioning aids and an experienced team, and its strongest evidence covers low- and favorable intermediate-risk disease with medium-term follow-up. Men with large prostates, marked urinary symptoms, high-risk cancer or a need for lymph node treatment are usually better served by the 20-session course, where evidence is longer and more complete. Guideline bodies describe SBRT as an option for selected men rather than a universal standard.

How long does each radiation session take?

The radiation itself lasts only a few minutes. Including changing, positioning and imaging checks, a conventional or 20-session appointment usually takes 15 to 30 minutes, while stereotactic sessions often run 20 to 40 minutes on the treatment table because alignment is verified more rigorously. Most men drive themselves, feel nothing during treatment and carry no radioactivity home afterward.

Does fewer sessions mean fewer side effects?

Not necessarily. Shorter courses divide a comparable total of radiation into larger fractions, so the overall tissue effect is similar. The CHHiP trial found comparable bowel and bladder side effects between 20 and 37 sessions at two years, and stereotactic trials report broadly similar totals with some differences in when urinary symptoms appear. What shorter courses reliably reduce is time and travel, not the underlying side-effect burden.

Why does the PSA not drop to zero after radiation?

Because the prostate remains in place after radiation, normal prostate cells continue producing small amounts of PSA. The level falls gradually over one to two years to a low point called the nadir rather than dropping to undetectable as it does after surgery. A temporary rise, known as a PSA bounce, is common within the first three years and is not a recurrence, so single readings are always repeated before conclusions are drawn.

How long is hormone therapy given with radiation?

Duration depends on risk group and is decided by the prescribing clinician. Low-risk disease usually needs none. Intermediate-risk disease typically involves a course of several months around the radiation, and high-risk disease often continues for a period of years because trials show longer courses improve control in that group. Hormone therapy lowers testosterone, which cancer cells need to grow, and its effects can outlast the radiation calendar by many months.

References

• NHS — Prostate cancer: Treatment
• CDC — Treatment of Prostate Cancer

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.